GSK plc ADR Stock
Price
Target price
€52.00
€52.00
-0.960%
-0.5
-0.960%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
The price for the GSK plc ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.960%).
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc ADR in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -0.960% | 4.418% | 27.451% | 46.893% | 24.402% | 54.762% | 45.455% |
| Bayer AG ADR | 0.000% | -0.855% | 16.000% | 107.143% | 31.818% | -21.088% | -14.074% |
| UCB S.A. | -2.540% | -0.823% | 8.660% | 54.399% | 16.807% | 253.069% | 232.574% |
| Novartis AG ADR | -1.080% | 0.727% | 13.061% | 35.122% | 16.878% | 70.567% | 89.726% |
Comments
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
Why Rapt Therapeutics Stock Soared Today
Shares of Rapt Therapeutics (NASDAQ: RAPT) surged on Tuesday after the immunology specialist struck a deal to be acquired by British pharmaceutical leader GSK (NYSE: GSK) for $2.2 billion.
By the
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit
ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 / OMP, a leader in supply chain planning solutions, is spotlighting at the Gartner Supply Chain Planning Summit 2025 in London how GSK is
